IMUX Immunic Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IMUX

Price (delayed)

$13.36

Market cap

$290.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.69

Enterprise value

$176.66M

Highlights
IMUX's equity has surged by 172% year-on-year but it is down by 13% since the previous quarter
The quick ratio has soared by 140% YoY but it has plunged by 54% from the previous quarter
The company's debt has surged by 96% YoY and by 36% QoQ
Immunic's net income has shrunk by 79% YoY and by 59% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: OTIC ORIC

Key stats

What are the main financial stats of IMUX
Market
Shares outstanding
21.75M
Market cap
$290.57M
Enterprise value
$176.66M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.06
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$70.06M
EBITDA
-$70.03M
Free cash flow
-$48.2M
Per share
EPS
-$3.69
Free cash flow per share
-$2.28
Book value per share
$6.49
Revenue per share
$0
TBVPS
$5.75
Balance sheet
Total assets
$154.72M
Total liabilities
$17.28M
Debt
$922,000
Equity
$137.45M
Working capital
$103.92M
Liquidity
Debt to equity
0.01
Current ratio
7.35
Quick ratio
7.02
Net debt/EBITDA
1.63
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-48.2%
Return on equity
-52.1%
Return on invested capital
N/A
Return on capital employed
-50.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMUX stock price

How has the Immunic stock price performed over time
Intraday
1.98%
1 week
-7.54%
1 month
6.88%
1 year
15.07%
YTD
-12.62%
QTD
-16.19%

Financial performance

How have Immunic's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$72.34M
Net income
-$70.06M
Gross margin
N/A
Net margin
N/A
Immunic's net income has shrunk by 79% YoY and by 59% QoQ
IMUX's operating income has dropped by 75% year-on-year and by 48% since the previous quarter

Growth

What is Immunic's growth rate over time

Valuation

What is Immunic stock price valuation
P/E
N/A
P/B
2.06
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 31% from the previous quarter
IMUX's equity has surged by 172% year-on-year but it is down by 13% since the previous quarter
The price to book (P/B) is 26% lower than the 5-year quarterly average of 2.8 but 3% higher than the last 4 quarters average of 2.0

Efficiency

How efficient is Immunic business performance
The company's return on equity fell by 33% QoQ but it rose by 20% YoY
The company's return on assets fell by 32% QoQ but it rose by 19% YoY

Dividends

What is IMUX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMUX.

Financial health

How did Immunic financials performed over time
The total assets has soared by 170% year-on-year but it is down by 8% since the previous quarter
IMUX's total liabilities has surged by 154% year-on-year and by 90% since the previous quarter
The company's debt is 99% lower than its equity
IMUX's equity has surged by 172% year-on-year but it is down by 13% since the previous quarter
The company's debt has surged by 96% YoY and by 36% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.